Alzamend Neuro
ALZN
15 hedge funds and large institutions have $9.41M invested in Alzamend Neuro in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 9 closing their positions.
1,044% more call options, than puts
Call options by funds: $652K | Put options by funds: $57K
249% more capital invested
Capital invested by funds: $2.7M → $9.41M (+$6.71M)
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
4.88% more ownership
Funds ownership: 3.43% → 8.31% (+4.9%)
25% less funds holding
Funds holding: 20 → 15 (-5)
56% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.11M |
| 2 |
BlackRock
New York
|
+$607K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$493K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$44K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$34.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$103K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$85.2K |
| 3 |
Renaissance Technologies
New York
|
-$56K |
| 4 |
Millennium Management
New York
|
-$43K |
| 5 |
KCIA
Kingsbury Capital Investment Advisors
Wilmette,
Illinois
|
-$22K |
ALZN Hedge Fund Activity: Q3 2022 in Review
15 of the 5,829 institutional investors tracked by Wall St. Rank reported a position in Alzamend Neuro (ALZN) for Q3 2022, worth a combined $9.41M — up 249% from $2.7M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of ALZN and 4 opened new positions — a net loss of 5 holders — while 1 trimmed existing stakes and 3 added.
The largest buyer was Vanguard Group, adding an estimated $4.11M. The largest seller was Citadel Advisors, exiting entirely with an estimated $103K sold.
- 15 institutional investors held Alzamend Neuro (ALZN) as of Q3 2022, down from 20 in Q2 2022.
- Funds reported $9.41M of Alzamend Neuro stock for Q3 2022, up 249% quarter-over-quarter.
- 4 funds opened new Alzamend Neuro positions in Q3 2022 and 9 closed out, a net change of -5 holders.
- The largest Alzamend Neuro buyer in Q3 2022 was Vanguard Group, an estimated $4.11M added.
- The largest Alzamend Neuro seller in Q3 2022 was Citadel Advisors, an estimated $103K sold.
Based on aggregated 13F filings for Q3 2022.